174 episodes
Medical News Podcast PeerDirect
-
- Health & Fitness
The Medical News Podcast by PeerDirect delivers news and interviews with clinical thought leaders and researchers to keep you informed of the latest breakthroughs, guidelines, and insights in your specialty. Designed for clinicians with stories selected by the PeerDirect editorial board. Visit us at peerdirect.com to sign-up for our newsletter.
-
Specialist Spotlight: Biosimilars in Retinal Medicine (Part 2)
Drs. David Eichenbaum and Priya Vakharia share their insights on biosimilars in the treatment of retinal disease in the United States.
-
Recovery possible for some patients with TBI removed from life support
Is there potential for recovery in patients who are withdrawn from life support? Find out about this and more in today's PeerDirect Medical News Podcast.
-
Specialist Spotlight: Biosimilars in Retinal Medicine (Part 1)
Drs. David Eichenbaum and Priya Vakharia share their insights on biosimilars in the treatment of retinal disease in the United States.
-
Specialist Spotlight: Urothelial Carcinoma Update From the ASCO GU Symposium 2024
Drs. Alicia Morgans and Jonathan Rosenberg share their insights into some interesting abstracts from the 2024 ASCO GU symposium: one covering a model to help predict response to neoadjuvant chemotherapy in patients with muscle invasive UC, and another regarding results from the PemCab study of pembrolizumab and cabozantinib in first‑line advanced UC.
-
ASCO Genitourinary Symposium 2024: Late‑Breaking Presentations on EV‑302 and AMBASSADOR
Drs. Jonathan Rosenberg and Alicia Morgans share their insights into some late-breaker abstracts presented at the 2024 ASCO GU symposium in San Francisco. The first is a subgroup analysis from EV‑302 with enfortumab vedotin and pembrolizumab, and the other is AMBASSADOR, which looks at adjuvant pembrolizumab in locally advanced and muscle invasive urothelial cancer.
-
Specialist Spotlight: Advanced Urothelial Carcinoma: Considerations in Therapeutic Sequencing
Drs. Alicia Morgans and Jonathan Rosenberg share their insights into therapeutic sequencing in patients with advanced urothelial cancer, reviewing patient selection and timing, options following progression on immunotherapy, and future therapeutic agents such as HER2‑targeted ADCs.